Conclusions:
- A lack of increased PLK1 expression suggests similar potential for PLK1 inhibitors in KRAS-MT tumors compared to KRAS-WT.
- Among PLK1 expression groups, proportionate increases in dMMR/MSI-H, TMB, and other immune related markers suggest a potential response to immunotherapy in tumors with increased PLK1 expression.
- Combining immunotherapy with a PLK1 inhibitor might be a synergistic approach to increase sensitivity in PLK1-overexpressing CRC regardless of KRAS status.